Aclaris therapeutics reports first quarter 2024 financial results and provides a corporate update

- progressing ati-2138 into atopic dermatitis - - management to host conference call at 5:00 pm et today - wayne, pa., may 07, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking